A microfluidics-based low-abundance biomarker detection kit, detection method and application thereof

Through microfluidic control technology combined with immune PCR, the non-specific reaction and low sensitivity of low abundance marker detection in complex biological samples was solved, and high sensitivity and high specificity detection of Alzheimer's markers were achieved, which significantly Improves the accuracy and feasibility of the diagnosis.

CN118667920BActive Publication Date: 2024-11-12BEIJING HUANUO AOMEI GENE BIOTECHNOLOGY CO LTD +1
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202411026081.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-12
Estimated Expiration
2044-07-30

AI Technical Summary

Technical Problem

The prior art is difficult to achieve high sensitivity and high specificity of low abundance biomarker detection in complex biological samples, especially in blood samples. Conventional detection methods have problems of nonspecific response and low sensitivity, limiting Alzhei Early diagnosis and early warning of diseases such as silent disease.

Method used

Using microfluidic technology combined with immune PCR, the antibody coupled to the oligonucleotide sequence binds to the antigen to be tested to form a complex, and is linked to form a nucleotide chain under the action of DNA ligase, and further formed through microfluidic technology. Single-molecule micro droplets are subjected to PCR reaction, and the droplet signal is read using the Poisson distribution principle for quantitative detection.

Benefits of technology

Accurate quantitative detection of low-abundance biomarkers, reduce non-specific reaction problems, improve the accuracy of detection results, significantly reduce blank limits, and improve the detection specificity and sensitivity of Alzheimer's markers , suitable for the on-site testing needs of clinical samples.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118667920B_ABST
    Figure CN118667920B_ABST
Patent Text Reader

Abstract

The present invention discloses a detection kit, a detection method and an application of a low-abundance biomarker based on microfluidics, which belongs to the detection field. The low-abundance biomarker includes an antigen protein; the detection kit includes: a first oligonucleotide sequence and a second oligonucleotide sequence (used to couple with a first and a second antibody that can bind to different sites of the antigen protein to be detected, and can connect the first and the second oligonucleotide sequences to form a nucleotide chain under the action of a ligase); a microfluidic chip, including a microdroplet generation chip and a microdroplet detection chip for detection. The present invention not only has high detection sensitivity, but also greatly reduces the nonspecific reaction problem caused by the high sensitivity of PCR due to the formation of single-molecule microdroplets, further guarantees the accuracy of the detection results, and solves the problem of high nonspecificity and low sensitivity of low-abundance markers in complex biological samples (such as blood samples).
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biological detection, and in particular to a detection kit, a detection method and an application thereof for low-abundance biomarkers based on microfluidics. Background Art

[0002] Alzheimer's Disease (AD) is a neurodegenerative disease. According to the data released in "2023 China Alzheimer's Disease Data and Prevention and Control Strategies", there are nearly 10 million Alzheimer's patients in my country. AD is a highly hidden disease in the early stages. As the disease progresses, the clinical manifestations are memory loss, weakened learning ability, emotional regulation disorders, and loss of motor skills. Alzheimer's disease not only seriously affects the patient's cognitive function and daily living ability, but also brings great pain and pressure to their relatives and friends. With the intensification of the global aging trend, more and more elderly people are facing the threat of AD. Early diagnosis and early warning of AD are the key to AD diagnosis and treatment, so it is crucial to establish an excellent AD early diagnostic marker detection program.

[0003] At present, the diagnosis of AD mainly relies on neuroimaging examinations (such as PET-MRI and PET-CT) and cerebrospinal fluid testing (such as β-amyloid protein testing). PET is expensive and radioactive, which makes it extremely difficult for medical sinking; and its value for early detection is very limited. The detection of cerebrospinal fluid biomarkers, such as Aβ42, Aβ40, p-tau181, and t-tau, can directly reflect the changes in the function and structure of the brain's nervous system and is a good auxiliary diagnostic indicator for AD. However, the acquisition of cerebrospinal fluid requires lumbar puncture, which is an invasive test, resulting in poor patient compliance and difficult to use for large-scale screening.

[0004] Peripheral blood is a good sample for biomarker detection due to its non-invasive, easy to obtain and stable characteristics. In recent years, researchers at home and abroad have been committed to the study of peripheral blood Alzheimer's disease biomarkers, predicting and diagnosing AD by detecting biomarkers in the blood. Studies have found that Aβ42, Aβ40, p-tau181, p-tau217, and p-tau231 in plasma can all be used as auxiliary diagnostic markers for AD, but due to their low content, as low as pg / mL or even fg / mL, existing conventional detection methods are difficult to detect these neurological markers in peripheral blood. Therefore, early diagnosis technology for AD blood markers is one of the most urgently needed areas for ultra-sensitive blood marker detection.

[0005] At present, the industry has also developed some ultra-sensitive detection methods for AD markers, such as electrochemiluminescence, high-resolution mass spectrometry and single-molecule immunoassay technology. At present, the world's most well-known ultra-sensitive AD detection technology is SimoA technology. SimoA technology is based on single-molecule immunoassay of microarray chips. By engraving (or pouring) thousands of micron-level microwells on millimeter-level chips, each microwell has a volume of about 40fL, the immune complex magnetic beads are distributed in the microwells, and the fluorescent spots are counted with the help of a high-resolution fluorescence microscope. According to the Poisson distribution theory, the ratio of the number of wells containing beads and fluorescent products at the same time to the total number of wells containing beads is calculated to determine the protein concentration in the test sample. SimoA technology combines magnetic bead enzyme-linked immunosorbent reaction with microwell array chips to achieve single-molecule protein detection, and the detection sensitivity can reach fg / mL. Although the technology has high detection sensitivity, the manual operation is complicated, the detection flux is fixed, and 24 samples must be detected at a time. Too few samples will cause huge waste of reagents and cannot achieve on-demand detection. In addition, the technology has high requirements for the configuration of detection equipment, which is not conducive to large-scale promotion and medical sinking. Similarly, Roche's electrochemiluminescence technology and Fujirebio's Lumipulse technology also face the problem of high precision and high price of detection equipment. Therefore, it is also necessary to establish a new ultra-sensitive blood marker detection method that does not rely on expensive high-precision detection equipment.

[0006] ImmunoPCR technology combines antigen-antibody reaction with PCR amplification technology, and is expected to become an ultra-sensitive detection scheme that is least dependent on high-precision equipment. Among them, the most representative is the proximity ligation assay (PLA). PLA is to simultaneously identify the object to be detected with two antibodies labeled with nucleic acid sequences. When these antibodies bind to the target object to be detected, the modified nucleic acid sequence is fixed at the adjacent position. These nucleic acid sequences are connected under the action of nuclear ligase, and the connected nucleic acid sequence is used as a template for subsequent nucleic acid amplification. This technology utilizes the signal amplification effect of PCR during exponential expansion and is a potential high-sensitivity detection technology method. However, this technology is difficult to apply to the detection of complex biological samples such as blood samples. Due to the complexity of blood samples, the background signal is relatively high, non-specific reactions are prone to occur, the probability of false positives is high, and there are problems of low detection efficiency and low sensitivity, which limits the application of proximity ligation technology in the detection of low-abundance markers in complex biological samples (such as blood samples). Some researchers have improved the proximity ligation technology into proximity extension technology and combined it with the second-generation sequencing technology to improve accuracy. This method is suitable for large-scale marker screening and exploratory scientific research. It cannot meet the requirements of testing clinical samples as soon as they arrive and only testing specific indicators. How to reduce the nonspecific reactions caused by complex components in blood samples during immune PCR testing is a key issue in promoting the application of immune PCR technology in clinical blood sample testing.

[0007] Therefore, there is an urgent need in this field to establish a simple, rapid, highly sensitive, specific, and stable method for detecting low-abundance proteins that is suitable for widespread clinical application and does not rely on high-precision equipment, and is low-cost and convenient. Summary of the invention

[0008] Purpose of the Invention

[0009] In order to overcome the above shortcomings, the purpose of the present invention is to provide a detection kit, detection method and application of low-abundance biomarkers based on microfluidics. The present invention independently develops microdrop immunoPCR (MiPCR), which forms a complex by coupling the first and second antibodies of the first and second oligonucleotide sequences to different epitopes of the antigen protein to be detected; and connects the first and second oligonucleotide sequences under the action of DNA ligase to obtain a connection product; further, the connection product is formed into a single-molecule micro-droplet by microfluidics technology for PCR reaction, and then the droplet signal is read using the Poisson distribution principle, thereby realizing accurate quantitative detection of the object to be detected. The present invention not only has high detection sensitivity, but also greatly reduces the non-specific reaction problem caused by the high sensitivity of PCR due to the formation of single-molecule micro-droplets, further guarantees the accuracy of the test results, and solves the problem of high non-specificity and low sensitivity of low-abundance markers in complex biological samples (such as blood samples).

[0010] Solution

[0011] To achieve the purpose of the present invention, the technical solution adopted by the present invention is as follows:

[0012] In a first aspect, the present invention provides a microfluidics-based detection kit for low-abundance biomarkers, wherein the low-abundance biomarkers include antigenic proteins, and the detection kit includes:

[0013] The first oligonucleotide sequence and the second oligonucleotide sequence are used to couple with the first and second antibodies that can bind to different sites of the antigen protein to be detected, respectively, and the first and second oligonucleotide sequences can be connected to form a nucleotide chain under the action of a ligase;

[0014] a primer pair and a probe for amplifying the nucleotide chain;

[0015] The microfluidic chip comprises a microdroplet generation chip and a microdroplet detection chip; the microdroplet generation chip is used for performing PCR reaction after generating microdroplets; the microdroplet detection chip is used for quantitatively detecting microdroplets after PCR.

[0016] In a second aspect, a microfluidics-based detection kit for low-abundance biomarkers is provided, wherein the low-abundance biomarkers include antigenic proteins, and the detection kit includes:

[0017] a complex of a first antibody coupled to a first oligonucleotide sequence;

[0018] a complex of a second antibody coupled to a second oligonucleotide sequence;

[0019] The first and second antibodies are used to bind to different sites of the antigen protein epitope to be detected respectively; the first and second nucleotide sequences are used to connect to form a nucleotide chain under the action of a ligase after the first and second antibodies bind to the antigen protein to be detected;

[0020] a primer pair and a probe for amplifying the nucleotide chain;

[0021] The microfluidic chip comprises a microdroplet generation chip and a microdroplet detection chip; the microdroplet generation chip is used for performing PCR reaction after generating microdroplets; the microdroplet detection chip is used for quantitatively detecting microdroplets after PCR.

[0022] In the first aspect or the second aspect, the first and second oligonucleotide sequences are selected from any one of the following combinations:

[0023] Combination 1: oligonucleotide sequences as shown in SEQ ID NO: 1 and SEQ ID NO: 2;

[0024] Combination 2: oligonucleotide sequences as shown in SEQ ID NO: 6 and SEQ ID NO: 7;

[0025] Combination 3: oligonucleotide sequences as shown in SEQ ID NO: 11 and SEQ ID NO: 12;

[0026] The 5' end of the first oligonucleotide sequence is labeled with an amino group; the 3' end of the second oligonucleotide sequence is labeled with an amino group.

[0027] In the first aspect or the second aspect, the nucleotide sequences of the primer pair and the probe used for amplification in combination 1 are shown in SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5.

[0028] In the first aspect or the second aspect, the nucleotide sequences of the primer pair and the probe used for amplification in combination 2 are shown in SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10.

[0029] In the first aspect or the second aspect, the nucleotide sequences of the primer pair and probe used for amplification in combination 3 are shown in SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 15.

[0030] The probe is labeled with a fluorescent group.

[0031] In the first aspect or the second aspect, it also comprises one or more of the following reagents 1)-6):

[0032] 1) Detection reagent C: a buffer containing Tris-HCl, sodium chloride, PEG8000, and proclin300; optionally, a buffer containing 0.025M Tris-HCl, 0.9% sodium chloride, 1% PEG8000, and 0.1% proclin300; Detection reagent C is used to dilute the sample to be tested;

[0033] 2) Detection Reagent D: Tris-HCl buffer containing ATP and DTT; optionally, 0.05 M Tris-HCl buffer containing 10 mM ATP and 50 μM DTT;

[0034] 3) Detection reagent E: DNA ligase (optionally at a concentration of 400 U / μL, optionally the DNA ligase is T4 DNA ligase), used to connect the first and second nucleotide sequences;

[0035] 4) Detection reagent F: contains Taq Enzyme, Mg 2+ , dNTP amplification system, used to mix with primer pairs and probes as a PCR amplification system; optionally containing 2× Taq Enzyme, 400nM primer probe, Mg 2+ , dNTP, ddH2O;

[0036] 5) Detection reagent G: including fluoro oil 7500 used as the oil phase;

[0037] 6) Calibrators and quality control products containing antigenic proteins.

[0038] Optionally, the calibrator or quality control is a 0.025M TBS buffer containing antigen protein and 1% BSA. Optionally, the concentration of the antigen in the calibrator or quality control is 5-20 pg / mL.

[0039] In the first aspect or the second aspect, the ratio of the water phase to the oil phase added to the microdroplet generation chip is 1:5-1:8, preferably, the ratio of the water phase to the oil phase added is 1:6.

[0040] In the first aspect or the second aspect, the loading amount of the ligation product used to form microdroplets is 2-5 μL, preferably 2 μL, wherein the ligation product comprises the first and second nucleotide sequences connected to form a nucleotide chain under the action of a ligase.

[0041] In the first aspect or the second aspect, the detection reagent (ie, detection reagent C) used to dilute the sample to be tested includes a buffer solution containing 0.025M Tris-HCl, 0.9% sodium chloride, 1% PEG8000, and 0.1% proclin300.

[0042] In the first aspect or the second aspect above, the antigen protein to be detected is one or more selected from the group consisting of marker antigen proteins for genetic diseases, marker antigen proteins for acquired diseases, marker antigen proteins for pathogens, and marker antigen proteins for infectious diseases.

[0043] In the first aspect or the second aspect above, the sample to be tested is one or more of plasma, serum, and cerebrospinal fluid.

[0044] In the first aspect or the second aspect above, the antigen protein marker is one or more of Aβ40, Aβ42, t-tau, p-tau181, p-tau217, and p-tau231.

[0045] In a third aspect, a method for detecting low-abundance biomarkers using the detection kit described in the first aspect is provided, characterized in that it comprises the following steps:

[0046] (1) Incubation: diluting the sample to be tested, adding a detection reagent containing a complex of a first antibody and a first oligonucleotide sequence, and a complex of a second antibody and a second oligonucleotide sequence, and incubating to obtain an incubation product;

[0047] (2) Ligation: connecting the first and second oligonucleotide sequences in the incubation product by DNA ligase to obtain a ligation product;

[0048] (3) Detection: The ligation product is added to the PCR amplification system as the water phase into the water wells of the microdroplet generation chip, and the oil phase reagent is added to the oil wells to generate microdroplets. PCR amplification is performed, and the amplified reaction products are detected through the microdroplet detection chip.

[0049] Furthermore, in step (1), detection reagent C is used for dilution, and detection reagent C is a buffer solution containing Tris, sodium chloride, PEG8000, and proclin300, and the volume ratio of detection reagent C to the sample to be tested is 1:1-1:5.

[0050] Furthermore, in step (2), the ligase system added to the incubation product includes a detection reagent D and a reagent E; wherein the detection reagent D is a Tris-HCl buffer containing ATP and DTT; and the detection reagent E is a DNA ligase.

[0051] Furthermore, in step (3), the PCR amplification system comprises a primer pair, a probe, Taq Enzyme, Mg 2+ , dNTP system.

[0052] Furthermore, in step (3), the ratio of the water phase to the oil phase is 1:5-1:8, preferably, the ratio of the water phase to the oil phase is 1:6.

[0053] Furthermore, in step (3), the loading amount of the ligation product used to form microdroplets is 2-5 μL, preferably, the loading amount is 2 μL.

[0054] In a fourth aspect, there is provided a use of the detection kit described in the first aspect or the method described in the second aspect in the preparation of a kit, chip or detection system for diagnosis, auxiliary diagnosis or prognostic evaluation of Alzheimer's disease.

[0055] Furthermore, the sample to be tested is one or more of plasma, serum, and cerebrospinal fluid.

[0056] Furthermore, the antigen protein marker is one or more of Aβ40, Aβ42, t-tau, p-tau181, p-tau217, and p-tau231, and can also be used to detect other low-abundance biomarkers.

[0057] Beneficial Effects

[0058] (1) The kit of the present invention adopts MiPCR technology, which has high detection sensitivity and high detection specificity, greatly reducing the problem of non-specific reaction of conventional or fluorescent PCR to complex biological samples (such as plasma). The blank limit of the detected biomarker is as low as 0.0137 pg / mL, which is a significant reduction of 52% compared with the conventional PLA detection technology (the blank limit of conventional PLA technology is 0.0288 pg / mL).

[0059] (2) The kit of the present invention can improve the differentiation between AD and non-AD: the AUC value of the biomarker expression level detected by the present invention for distinguishing between the AD group and non-AD dementia is as high as 0.8278, which significantly improves the specificity by 13.04%, and increases the accuracy of the detection results of low-abundance biomarkers in complex biological samples.

[0060] (3) The present invention uses simple equipment and operation: The present invention does not involve complex and expensive detection equipment, and conventional PCR, microfluidic droplet production and detection instruments are sufficient, which is more conducive to the promotion and popularization of technology.

[0061] (4) The kit of the present invention has lower requirements for sample quality: The technology of the present invention has better detection ability for old samples. It still has excellent detection performance for old samples stored within 1.5-2 years, and there is still a significant difference in p-tau181 between the AD group and the non-AD group (there is no difference between the two groups with conventional PLA technology); the corresponding AUC value of the ROC curve is 0.72 (the AUC value of conventional PLA technology is only 0.59). BRIEF DESCRIPTION OF THE DRAWINGS

[0062] One or more embodiments are exemplarily described by the pictures in the accompanying drawings, and these exemplary descriptions do not constitute limitations on the embodiments. The special word "exemplary" here means "used as an example, embodiment or illustrative". Any embodiment described as "exemplary" here is not necessarily interpreted as being superior or better than other embodiments.

[0063] Figure 1 The reaction strengths of different combinations of oligonucleotides and primer probes in Example 1 of the present invention are shown.

[0064] Figure 2 The screening results of the microfluidic system established in Example 2 of the present invention, wherein A is the result of conventional PLA technology samples, B is the result of conventional PLA technology method transferred to MiPCR samples of the present invention, C is the result of optimizing the water-oil ratio by MiPCR technology of the present invention, D is the result of optimizing the sample amount by MiPCR technology of the present invention, and E is the result of optimizing the dilution by MiPCR technology of the present invention.

[0065] Figure 3 The standard curve of Test Example 2 of the present invention is drawn, wherein A is the standard curve drawn by the conventional PLA technology of Comparative Example 1, and B is the standard curve drawn by the preferred microfluidic reaction system of Example 2.

[0066] Figure 4 The ROC curve levels of plasma p-tau181 levels for AD and non-AD patients detected by different detection methods of Test Example 4 of the present invention.

[0067] Figure 5 This is the ROC curve level of AD and non-AD patients in detecting the p-tau181 level in old plasma samples using different detection methods of Test Example 5 of the present invention.

[0068] Figure 6 This is the Aβ40 standard curve drawn using MiPCR technology in Test Example 6 of the present invention.

[0069] Figure 7 This is the Aβ42 standard curve drawn using MiPCR technology in Test Example 6 of the present invention.

[0070] Figure 8 This is the result of using MiPCR technology to detect the concentrations of Aβ40 and Aβ42 in AD and non-AD plasma in Test Example 6 of the present invention.

[0071] Fig. 9 This is the ROC curve level of AD and non-AD patients using MiPCR technology to detect the concentrations of Aβ40 and Aβ42 in plasma in Test Example 6 of the present invention. DETAILED DESCRIPTION

[0072] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be described clearly and completely below. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0073] In addition, in order to better illustrate the present invention, numerous specific details are provided in the specific embodiments below. It should be understood by those skilled in the art that the present invention can also be implemented without certain specific details. In some embodiments, raw materials, elements, methods, means, etc. well known to those skilled in the art are not described in detail, so as to highlight the main purpose of the present invention.

[0074] Unless explicitly stated otherwise, throughout the specification and claims, the term “comprise” or variations such as “include” or “comprising”, etc., will be understood to include the stated elements or components but not to exclude other elements or components.

[0075] The raw materials used in the present invention are all commercially available. For example, anti-human p-tau181 antibodies were purchased from Nanjing Okey Biotechnology Co., Ltd. p-tau181 antibody pair (item number: H484c7 and R486c5), p-tau181 antigen was purchased from Beijing Baixinyi Biotechnology Co., Ltd. (item number: A09N01-C9), and microfluidic generation chips and detection chips were purchased from Tianjin Fande Biotechnology Co., Ltd.

[0076] The present invention has newly created a microdrop immuno PCR technology (Microdrop immuno PCR, MiPCR). The present invention forms a complex with the antigen protein to be tested by coupling an antibody pair with a specific oligonucleotide sequence. The oligonucleotide chain on the antibody pair forms a ligation product under the action of DNA ligase. The ligation product is further formed into a single-molecule microdroplet by microfluidics technology for PCR reaction, and then the droplet signal is read using the Poisson distribution principle, thereby achieving accurate quantitative detection of the object to be tested. The present invention not only has high detection sensitivity, but also greatly reduces the non-specific reaction problem caused by the high sensitivity of PCR due to the formation of single-molecule microdroplets, further guarantees the accuracy of the test results, and overcomes the deficiency of traditional proximity ligation technology that it is difficult to detect complex clinical samples (such as blood) with high sensitivity.

[0077] In order to better illustrate the characteristics of the present invention, the following is an example of the classic Alzheimer's disease (AD) marker p-tau181. The technical solution of the present invention is as follows:

[0078] The main components of the kit for ultrasensitively detecting AD marker p-tau181 of the present invention are shown in Table 1:

[0079] Table 1. Composition of the kit for ultrasensitive detection of AD marker p-tau181 of the present invention

[0080] .

[0081] The ultrasensitive AD marker detection method of the present invention comprises the following steps:

[0082] (1) Incubation: Use detection reagent C to dilute the sample to be tested at a volume ratio of 1:1-1:5, preferably, at a volume ratio of 1:1. Add 5 μL of detection reagents A and B respectively to a 0.2 mL PCR tube; then add 40 μL-90 μL of the diluted sample to be tested, preferably 40 μL, and incubate at 37°C for 30 min.

[0083] (2) Ligation: Add 10 μL of the above incubation product and 1 μL of detection reagent D and 1 μL of detection reagent E into a 0.2 mL PCR tube in sequence, place in a PCR instrument and react at 25°C for 30 min, then react at 65°C for 10 min to obtain a ligation product.

[0084] (3) Detection: Take 2 μL of the ligation product from step (2) and 28 μL of detection reagent F and add them to the water wells of the microdroplet generation chip (purchased from Vander Biotech), add 180 μL of detection reagent G to the oil wells of the microdroplet generation chip, place the microdroplet generation chip in the sample preparation instrument, run the instrument to generate microdroplets. The prepared microdroplets are reacted according to 95°C for 10 min; 94°C for 30 s, 60°C for 1 min, 40 cycles; 12°C for 5 min. The PCR product after the reaction is placed in a microdroplet detection chip (purchased from Vander Biotech), and detection reagent F is added to the corresponding wells. The detection chip is placed in a biochip analyzer for detection.

[0085] (4) Data analysis: Draw a standard curve based on the copy number of the calibrator displayed in the chip analysis software, and calculate the concentration of p-tau181 in the sample according to the standard curve.

[0086] Due to the complexity of clinical samples (blood), the background is high and the detection sensitivity is low. In order to overcome this problem, the inventors have conducted a large number of research and development experiments, including but not limited to the screening of the following embodiments:

[0087] Example 1. Screening of antibody-conjugated oligonucleotides

[0088] Due to the complexity of clinical samples (blood), there are many interfering factors. Whether the coupled oligonucleotides can resist interference is uncertain. The inventors designed many oligonucleotide sequences to obtain oligonucleotide sequences that can resist interference. Some sequences are shown in Table 2:

[0089] Table 2. Combinations of three oligonucleotides

[0090] .

[0091] In Table 2, markers are designed in the sequences of Oligo1-6 and probes OLP1-3. Since markers are difficult to reflect in the sequence table, they are all expressed in the form of SEQ ID NO: n (n is the corresponding sequence number) for uniform expression.

[0092] Verify the above oligonucleotide combination: select the p-tau181 antibody pair (Cat. No.: H484c7 and R486c5) of Nanjing Okey Biotech Co., Ltd., and use the abcam (Cat. No. ab218260) oligonucleotide-protein coupling kit to couple the oligonucleotide and antibody pair. The operation process is carried out according to the instructions. After the coupling is completed, verify the effect of the oligonucleotide and the corresponding primer probe combination. The verification steps are as follows:

[0093] (i) Incubation: Add 5 μL of antibody-oligonucleotide conjugate and 40 μL of the test substance to a 0.2 mL PCR tube and incubate at 37°C for 30 min.

[0094] (ii) Ligation: Add 10 μL of the incubation product from step (i) above, 1 μL of detection reagent C, and 1 μL of detection reagent D into a 0.2 mL PCR tube, place in a PCR instrument and react at 25°C for 30 min, then at 65°C for 10 min.

[0095] (iii) Detection: Take 10 μL of the reaction product of (ii) and 20 μL of detection reagent F and add them to a 0.2 mL eight-tube strip. Run the fluorescence quantitative PCR instrument (ABI7500) for 40 cycles of 95°C for 10 min, 95°C for 30 s, and 60°C for 30 s.

[0096] (iv) Analysis: The Ct value results of fluorescent quantitative PCR are as follows: Figure 1 As shown, the fluorescence signal intensity is: combination 2> combination 3> combination 1, so the oligonucleotide and primer probe of combination 2 are selected for subsequent detection.

[0097] Example 2: Establishment of microfluidic reaction system

[0098] After screening suitable oligonucleotides and other raw materials, the research team plans to further establish a microfluidic technology platform. When using the traditional PLA solution to translate and establish a microfluidic system, it was found that there were obvious detection signals on the traditional PLA platform (such as Figure 2 A in the figure) However, no droplets are generated during the microfluidic process, and no detection signals are found (e.g. Figure 2B in the figure). Considering the complexity of the blood sample matrix (which contains a variety of human metabolites and proteins, and the composition is extremely complex), we speculate that the complexity of the blood sample has a huge interference with the formation of microdroplets and the PCR reaction in the microdroplets, so there is no signal. At present, there is no precedent for directly using microfluidics technology to perform immune PCR to detect the protein content in blood. In order to further overcome the interference of the blood sample matrix on the formation and reaction of microdroplets, the inventors have made many attempts and finally found some key points that can solve this problem, including the exploration of adjusting the water-oil ratio, sample volume, reaction diluent and other conditions. The following describes the effective adjustment scheme in detail:

[0099] First, in order to form effective microdroplets, the inventors adjusted the water-oil ratio in the system used to generate microdroplets through repeated tests, that is, adjusted the water-oil ratio in the water holes and oil holes in the microdroplet generation chip. When the water-oil volume ratio was 1:2, there was almost no signal, such as Figure 2 The right figure of C in FIG. 1 shows that when the water-oil ratio is 1:6, the signal intensity is higher, such as Figure 2 In the left figure of C, preferably, there is a signal when the water-oil ratio is 1:5-1:8, but the signal intensity cannot meet the detection requirements.

[0100] Furthermore, the inventors adjusted the sample loading volume for generating microdroplets (i.e., the loading volume of the ligation product in step (3)). When the loading volume was 10 μL, there was almost no signal, as shown in FIG. Figure 2 The left picture of D in the figure; when the sample volume is μL, the signal is stronger, such as Figure 2 The right figure of D in FIG. 1 ; preferably, a stronger signal is obtained when the sample loading amount is 2-5 μL.

[0101] To further enhance the reaction signal, the inventors tried to see whether different buffers could improve the reaction efficiency. Different diluents (corresponding to the detection reagent C in the kit) used to dilute the sample in step (1) included diluent 1 (a buffer containing 0.025M Tris-HCl, 0.9% sodium chloride, 1% PEG8000, and 0.1% proclin300, i.e., the detection reagent C in the kit), diluent 2 (a buffer containing 0.5M Tris-HCl, 0.9% sodium chloride, and 0.1% proclin300), and diluent 3 (a buffer containing 0.025M Tris-HCl, 0.9% sodium chloride, 1% PEG6000, and 0.1% proclin300). The results showed that diluent 1 (i.e., the detection reagent C in the kit) had the strongest signal (e.g., Figure 2 In the left figure of E), dilutions 2 and 3 are of comparable strength (e.g. Figure 2 (the two right sides of E in Figure 1).

[0102] The optimal microfluidic reaction system with a water-oil volume ratio of 1:6, a sample volume of 2 μL, and a diluent of 1 was used for the best detection effect. Specifically:

[0103] (1) Incubation: Dilute the sample to be tested with detection reagent C at a ratio of 1:1-1:5, preferably 1:1. Add 5 μL of detection reagents A and B respectively to a 0.2 mL PCR tube; then add 40 μL-90 μL of the diluted sample to be tested, preferably 40 μL. Incubate at 37°C for 30 min.

[0104] (2) Ligation: Add 10 μL of the above incubation product, 1 μL of detection reagent D and 1 μL of detection reagent E into a 0.2 mL PCR tube in sequence, place in a PCR instrument and react at 25°C for 30 min, then react at 65°C for 10 min to obtain a ligation product.

[0105] (3) Detection: Add 2 μL of the ligation product and 28 μL of detection reagent F to the water well of the microdroplet generation chip, and add 180 μL of detection reagent G (Fluoro Oil 7500) to the oil well of the microdroplet generation chip. Place the generation chip containing microdroplets into the sample preparation instrument, run the instrument, and generate microdroplets. The prepared microdroplets are reacted according to 95°C for 10 min; 94°C for 30 s, 60°C for 1 min, 40 cycles; and 12°C for 5 min.

[0106] (4) Analysis: Place the reaction product in a microdroplet detection chip, add detection reagent F to the corresponding well, and place the detection chip in a biochip analyzer for detection to obtain the copy number. The sample concentration can be calculated by drawing a standard curve.

[0107] Comparative Example 1: Conventional PLA Technology

[0108] Conventional PLA technology refers to directly performing fluorescent quantitative PCR without generating microdroplets (i.e., the method for verifying the effect of oligonucleotides in Example 1), and the specific steps are as follows:

[0109] (i) Incubation: Add 5 μL of antibody-oligonucleotide conjugate and 40 nucleotides of the analyte to a 0.2 mL PCR tube and incubate at 37°C for 30 min.

[0110] (ii) Ligation: Add 10 μL of the incubation product from step (i) above, 1 μL of detection reagent C, and 1 μL of detection reagent D into a 0.2 mL PCR tube, place in a PCR instrument and react at 25°C for 30 min, then at 65°C for 10 min.

[0111] (iii) Detection: Take 10 μL of the reaction product of (ii) and 20 μL of detection reagent F and add them to a 0.2 mL eight-tube strip. Run the fluorescence quantitative PCR instrument (ABI7500) for 40 cycles of 95°C for 10 min, 95°C for 30 s, and 60°C for 30 s.

[0112] (iv) Data analysis: The concentration can be calculated based on the Ct value detected in the fluorescence quantitative PCR instrument.

[0113] Test Example 1: Standard curve and linear range analysis

[0114] The p-tau181 antigen was diluted to different concentrations using 0.025M TBS buffer containing 1% BSA: 100pg / mL, 50pg / mL, 25pg / mL, 10pg / mL, 5pg / mL, 1pg / mL, and 0.1pg / mL. The p-tau181 antigen of different concentrations was detected by the preferred microfluidic reaction system of Example 2 (referred to as MiPCR) and the conventional PLA technology of Comparative Example 1 (referred to as PLA) to draw standard curves. The test results are shown in Table 3, and the standard curve drawn by the test results is shown in Table 4. Figure 3 .

[0115] Table 3. Standard test concentrations

[0116] .

[0117] Table 3 and Figure 3 The results show that after fitting analysis of the standard curves of the conventional PLA technology (Comparative Example 1) and the MiPCR technology of the present invention, it is found that the standard curve obtained by the conventional PLA technology (Comparative Example 1) needs to be fitted by a quadratic function, and the fitting correlation coefficient R 2 >0.99 (the correlation coefficient using a linear function fitting is only 0.85); the linear function of the standard curve fitting curve of the present invention (MiPCR) shows the correlation coefficient R 2 >0.99. It can be seen that the present invention has a better linear range than the conventional PLA technology, and the linear range can reach [0.1-100 pg / mL], while the linear fitting correlation coefficient of comparative example 1 is only 0.85, which does not meet the linear requirement.

[0118] Test Example 2, Blank Limit

[0119] The zero-concentration calibrator was used as a sample, and the test was repeated 20 times by the preferred microfluidic reaction system (referred to as MiPCR) of Example 2 and the conventional PLA technology of Comparative Example 1, and the copy numbers of the 20 test results were obtained (as shown in Table 4), and the average value was calculated. The standard deviation X (SD) was obtained by performing a two-point regression fit based on the concentration-signal value results between the zero-concentration calibrator (0 pg / mL: copy number 2079.57) and the adjacent calibrator (0.1 pg / mL: copy number 7624.64) to obtain a linear equation (fitting formula: y = 55451x + 2079.6; R 2 =1), +2SD) into the above equation, and the corresponding concentration value is obtained, which is the blank limit. It is calculated that the detection blank limit of the kit of the present invention can reach 0.0137pg / mL. The conventional PLA method performs a two-point regression fitting based on the concentration-signal value results between the zero-concentration calibrator (0pg / mL: Ct value 31.14) and the adjacent calibrator (0.1pg / mL: Ct value 29.03) to obtain a linear equation (fitting formula: y=-21.08x+31.14; R 2 =1), Substituting the Ct value corresponding to the concentration of 0.0277pg / mL into the above equation, the blank limit is 0.0288pg / mL. It can be seen that the blank limit of the technical method of the present invention is significantly reduced by 52% compared with the conventional PLA technology.

[0120] Table 4. p-tau181 blank limit results

[0121] .

[0122] Test Example 3: Repeatability

[0123] The quality control products 1 and 2 were respectively detected by the preferred microfluidic reaction system (MiPCR for short) of Example 2 and the conventional PLA technology of Comparative Example 1. In the same batch analysis, the quality control products 1 and 2 were repeatedly detected 10 times, and the average value of the 10 test results was calculated. and standard deviation SD . Calculate the coefficient of variation according to formula (1) CV ), the coefficient of variation (CV, %) must be ≤10.0%. The results are shown in Table 5.

[0124] ;

[0125] Among them, in formula (1):

[0126] - the average value of the measurement results;

[0127] SD – standard deviation of sample test values;

[0128] CV - coefficient of variation (%).

[0129] Table 5. p-tau181 repeatability test results

[0130] ;

[0131] Table 5 shows that the CV of the high-concentration quality control product of the present invention is 5.99%, and the CV of the low-concentration quality control product is 8.05%, both of which are better than conventional PLA (the CV of the high-concentration quality control product of conventional PLA is 8.95%, and the CV of the low-concentration quality control product is 12.18%).

[0132] Test Example 4: Auxiliary detection capability for AD and non-AD

[0133] The kit (MiPCR p-tau181) of Table 1 of the present invention (using the preferred method of Example 2) and the conventional PLA technology (p-tau181) of Comparative Example 1 were used to perform p-tau181 detection on 46 Aβ+ (AD) samples and 32 Aβ- (non-AD) plasma samples (all included samples were identified as AD and non-AD by PIB PET), and the test results are shown in Table 6.

[0134] Table 6. Detection results of the kit of the present invention for Aβ+ and Aβ- samples

[0135] ;

[0136] The ROC curve was further drawn using Graphpad9.5.1 for the test results (such as Figure 4 ), the results show that the AUC value of the conventional PLA technology in comparative example 1 for detecting the expression level of p-tau181 in plasma for AD and non-AD is 0.7181 (sensitivity is 75%, specificity is 60.87%). The AUC value of the MiPCR technology of the present invention for detecting the expression level of p-tau181 in plasma for AD and non-AD is 0.8278 (sensitivity is 75%, specificity is 73.91%). Comprehensive comparison shows that the present invention can improve the ability to distinguish between AD and non-AD, especially significantly improve the specificity by 13.04%. It further illustrates that the MiPCR technology of the present invention can improve the detection sensitivity, greatly avoid the background interference and of plasma samples, thereby effectively improving the diagnostic performance of AD, and also bring more application prospects for the detection of other low-abundance plasma markers.

[0137] Test Example 5: Detection of old samples

[0138] In clinical sample testing, it is often encountered that old samples cannot be tested due to the long storage period. In order to test the detection ability of the present invention for plasma samples with a storage period of 1.5-2 years, we selected 24 patients diagnosed with AD by clinical experts and 25 patients with other dementias other than AD. The plasma of the above samples in the sample library was tested for p-tau181 in the old plasma samples using the kit (MiPCR p-tau181) in Table 1 provided by the present invention (using the preferred method of Example 2) and the conventional PLA technology of Comparative Example 1. The test results were statistically analyzed using Graphpad9.5.1 and the ROC curve was drawn. The results are shown as follows: Figure 5 .

[0139] Figure 5 The results showed that for old AD and non-AD samples, the conventional PLA technology of comparative example 1 had poor discrimination of p-tau181, and there was no significant difference between the two groups of samples, with an AUC of 0.59; while the p-tau181 detection of the present invention could well distinguish old AD and non-AD samples, and the results between the two groups were still significantly different, with an AUC of 0.72. This result shows that the present invention still has excellent detection ability for old samples, that is, it has stronger anti-interference ability and reduces the background noise of plasma samples.

[0140] From the above test examples, it can be seen that the present invention provides an ultra-sensitive detection method for plasma AD marker p-tau181 with a detection blank limit as low as 0.0137pg / mL and a linear range of 0.1-100pg / mL based on microfluidic technology. The kit provided by the present invention can efficiently detect the level of p-tau181 in plasma, improve the discrimination between AD and non-AD dementia samples, and the AUC value is as high as 0.8278, which significantly improves the specificity by 13.04%, and can effectively improve the detection ability of low-abundance protein markers and improve the diagnostic level.

[0141] In addition, the present invention still has excellent detection performance for old samples stored within 1.5-2 years, and still has significant differences in plasma p-tau181 between AD and non-AD dementia samples (conventional PLA technology shows no difference), and the corresponding AUC value of the ROC curve is AUC 0.72 (the AUC value of conventional PLA technology is only 0.59).

[0142] Test Example 6: Detection of other markers:

[0143] The present invention also performs detection of Aβ40 and Aβ42 markers, specifically:

[0144] 1) Aβ40 antibody coupling and standard curve drawing: Oligo3 and Oligo4 oligonucleotide sequences in combination 2 of Table 2 were coupled with Aβ40 antibody M1501 and antibody M1503 (purchased from Hangzhou Huakui Jinpei Biotechnology Co., Ltd.) respectively (i.e., the p-tau181 antibody pair in reagents A and B in Table 1 was replaced with Aβ40 antibody M1501 and antibody M1503), and different concentrations of Aβ40 antigen AMYD-009A (purchased from Zhongpeptide Biochemical Co., Ltd.) were respectively detected with reference to the preferred microfluidic reaction system of Example 2 (referred to as MiPCR), and the standard curve drawn by the detection results was as shown in the figure. Figure 6 As shown, the linear range is [1-1000pg / mL].

[0145] 2) Aβ42 antibody coupling and standard curve drawing: Oligo3 and Oligo4 in combination 2 of Table 2 were coupled with Aβ42 antibody M051105M and antibody M051112M (Nanjing Fuxiao Biotechnology Co., Ltd.) respectively (i.e., the p-tau181 antibody pair in reagents A and B in Table 1 was replaced with Aβ42 antibody M051105M and antibody M051112M), and different concentrations of Aβ42 antigen AMYD-003A (purchased from Zhongpeptide Biochemical Co., Ltd.) were respectively detected with reference to the preferred microfluidic reaction system in Example 2 (referred to as MiPCR), and the standard curve drawn by the detection results was as shown in the figure. Figure 7 As shown, the linear range is [1-500pg / mL].

[0146] 3) Ability of MiPCR to detect Aβ42 and Aβ40 in AD and non-AD plasma: Using the above 1) and 2) coupled Aβ40 antibodies and Aβ42 antibodies, the Aβ42 and Aβ40 concentrations of 12 Aβ+ (AD) samples and 12 Aβ- (non-AD) plasma samples (all included samples were identified as AD and non-AD by PIB PET) were detected with reference to the preferred microfluidic reaction system in Example 2. The test results are as follows: Figure 8 , Fig. 9 The results showed that the expression levels of Aβ42 and Aβ40 in plasma samples of non-AD and AD groups were detected by MiPCR. p The values ​​were all <0.05, which were significantly different; the AUC value of Aβ42 expression level for AD and non-AD was 0.7708 (sensitivity was 75%, specificity was 75%), and the AUC value of Aβ40 expression level for AD and non-AD was 0.7569 (sensitivity was 75%, specificity was 66.67%), indicating that the MiPCR technology of the present invention also has a good effect on the detection of Aβ40 and Aβ42.

[0147] In summary, the use of the MiPCR technology of the present invention can realize the detection of AD antigen markers including but not limited to Aβ40, Aβ42, and p-tau181. The present invention has the characteristics of high detection sensitivity and wide linear range, and can solve the problem of high nonspecificity and low sensitivity of low-abundance markers in complex biological samples (such as blood samples). The detection method of the present invention will greatly improve the current clinical dilemma of low-abundance AD ​​blood marker detection, fill the gap of my country's independent intellectual property rights AD plasma marker detection method, and the present invention will greatly benefit the prevention and treatment of Alzheimer's disease in my country, and is also of great significance for the detection of other low-abundance protein markers.

[0148] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A microfluidics-based detection kit for low-abundance biomarkers, wherein the low-abundance biomarkers include antigenic proteins, and the sample to be tested is one or more of plasma, serum, and cerebrospinal fluid, characterized in that: The test kit includes: Detection reagent C used to dilute the sample to be tested, including a buffer containing 0.025MTris-HCl, 0.9% sodium chloride, 1%PEG8000, and 0.1%proclin300; The first oligonucleotide sequence and the second oligonucleotide sequence are used to couple with the first and second antibodies that can bind to different sites of the antigen protein to be detected, respectively, and the first and second oligonucleotide sequences can be connected to form a nucleotide chain under the action of a ligase; a primer pair and a probe for amplifying the nucleotide chain; The microfluidic chip comprises a microdroplet generation chip and a microdroplet detection chip; the microdroplet generation chip is used for performing PCR reaction after generating microdroplets; the microdroplet detection chip is used for quantitatively detecting microdroplets after PCR.

2. The detection kit according to claim 1, characterized in that The first and second oligonucleotide sequences are selected from any one of the following combinations: Combination 1: oligonucleotide sequences as shown in SEQ ID NO: 1 and SEQ ID NO: 2; Combination 2: oligonucleotide sequences as shown in SEQ ID NO: 6 and SEQ ID NO: 7; Combination 3: oligonucleotide sequences as shown in SEQ ID NO: 11 and SEQ ID NO: 12; The 5' end of the first oligonucleotide sequence is labeled with an amino group; the 3' end of the second oligonucleotide sequence is labeled with an amino group.

3. The detection kit according to claim 2, characterized in that The nucleotide sequences of the primer pair and probe used for amplification in combination 1 are shown in SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5; The nucleotide sequences of the primer pair and probe used for amplification with combination 2 are shown in SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10; The nucleotide sequences of the primer pair and probe used for amplification with combination 3 are shown in SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 15; The probe is labeled with a fluorescent group.

4. The detection kit according to claim 2, characterized in that It also contains one or more of the following reagents 2)-6): 2) Detection reagent D: Tris-HCl buffer containing ATP and DTT; 3) Detection reagent E: DNA ligase, used to connect the first and second nucleotide sequences; 4) Detection reagent F: contains Taq Enzyme, Mg 2+ , dNTP amplification system, used to mix with primer pairs and probes as a PCR amplification system; 5) Detection reagent G: including fluoro oil 7500 used as the oil phase; 6) Calibrators and quality control products containing the antigen protein to be tested.

5. The detection kit according to any one of claims 1 to 4, characterized in that: The ratio of water phase to oil phase added to the microdroplet generation chip is 1:5-1:8; And / or, the loading amount of the ligation product used to form microdroplets is 2-5 μL; wherein the ligation product comprises a product obtained by ligating the first and second nucleotide sequences under the action of a ligase; And / or, the antigen protein to be tested is selected from one or more of the marker antigen proteins of genetic diseases, marker antigen proteins of acquired diseases, marker antigen proteins of pathogens, and marker antigen proteins of infectious diseases; And / or, the antigen protein marker is one or more of Aβ40, Aβ42, t-tau, p-tau181, p-tau217, and p-tau231.

6. Use of a detection kit in the preparation of a product for detecting low-abundance biomarkers in plasma, serum or cerebrospinal fluid samples, characterized in that: The test kit includes: Detection reagent C used to dilute the sample to be tested, including a buffer containing 0.025MTris-HCl, 0.9% sodium chloride, 1%PEG8000, and 0.1%proclin300; a first antibody complex coupled to a first oligonucleotide sequence; a second antibody complex coupled to a second oligonucleotide sequence; The first and second antibodies are used to bind to different sites of the antigen protein epitope to be detected respectively; the first and second nucleotide sequences are used to connect to form a nucleotide chain under the action of a ligase after the first and second antibodies bind to the antigen protein to be detected; a primer pair and a probe for amplifying the nucleotide chain; The microfluidic chip comprises a microdroplet generation chip and a microdroplet detection chip; the microdroplet generation chip is used for performing PCR reaction after generating microdroplets; the microdroplet detection chip is used for quantitatively detecting microdroplets after PCR.

7. The use according to claim 6, characterized in that: The first and second oligonucleotide sequences are selected from any one of the following combinations: Combination 1: oligonucleotide sequences as shown in SEQ ID NO: 1 and SEQ ID NO: 2; Combination 2: oligonucleotide sequences as shown in SEQ ID NO: 6 and SEQ ID NO: 7; Combination 3: oligonucleotide sequences as shown in SEQ ID NO: 11 and SEQ ID NO: 12; The 5' end of the first oligonucleotide sequence is labeled with an amino group; the 3' end of the second oligonucleotide sequence is labeled with an amino group.

8. The use according to claim 6, characterized in that: The nucleotide sequences of the primer pair and probe used for amplification in combination 1 are shown in SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5; The nucleotide sequences of the primer pair and probe used for amplification with combination 2 are shown in SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10; The nucleotide sequences of the primer pair and probe used for amplification with combination 3 are shown in SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 15; The probe is labeled with a fluorescent group.

9. The use according to claim 8, characterized in that: It also contains one or more of the following reagents 2)-6): 2) Detection reagent D: Tris-HCl buffer containing ATP and DTT; 3) Detection reagent E: DNA ligase, used to connect the first and second nucleotide sequences; 4) Detection reagent F: contains Taq Enzyme, Mg 2+ , dNTP amplification system, used to mix with primer pairs and probes as a PCR amplification system; 5) Detection reagent G: including fluoro oil 7500 used as the oil phase; 6) Calibrators and quality control products containing the antigen protein to be tested.

10. The use according to any one of claims 6 to 9, characterized in that: The ratio of water phase to oil phase added to the microdroplet generation chip is 1:5-1:8; And / or, the loading amount of the ligation product used to form microdroplets is 2-5 μL; wherein the ligation product comprises a product obtained by ligating the first and second nucleotide sequences under the action of a ligase; And / or, the antigen protein to be tested is selected from one or more of the marker antigen proteins of genetic diseases, marker antigen proteins of acquired diseases, marker antigen proteins of pathogens, and marker antigen proteins of infectious diseases; And / or, the antigen protein marker is one or more of Aβ40, Aβ42, t-tau, p-tau181, p-tau217, and p-tau231.

11. A method for detecting low-abundance biomarkers for non-diagnostic purposes using the detection kit according to any one of claims 1 to 5, characterized in that: It includes the following steps: (1) Incubation: diluting the sample to be tested, adding a detection reagent containing a complex of a first antibody and a first oligonucleotide sequence, and a complex of a second antibody and a second oligonucleotide sequence, and incubating to obtain an incubation product; (2) Ligation: connecting the first and second oligonucleotide sequences in the incubation product by DNA ligase to obtain a ligation product; (3) Detection: The ligation product is added to the PCR amplification system as the water phase into the water wells of the microdroplet generation chip, and the oil phase reagent is added to the oil wells to generate microdroplets. PCR amplification is performed, and the amplified reaction products are detected through the microdroplet detection chip.

12. The method for non-diagnostic purposes according to claim 11, characterized in that: In step (1), the sample is diluted with detection reagent C, which is a buffer solution containing Tris-HCl, sodium chloride, PEG8000, and proclin300, and the volume ratio of detection reagent C to the sample to be tested is 1:1-1:5; And / or, in step (2), the ligase system added to the incubation product includes a detection reagent D and a reagent E; wherein the detection reagent D is a Tris-HCl buffer containing ATP and DTT; and the detection reagent E is a DNA ligase; And / or, in step (3), the PCR amplification system comprises a primer pair, a probe, Taq Enzyme, Mg 2+ , dNTP system; And / or, in step (3), the ratio of the water phase to the oil phase is 1:5-1:8; And / or, in step (3), the loading volume of the ligation product used to form microdroplets is 2-5 μL.

13. Use of the detection kit according to any one of claims 1 to 5 or the method according to claim 11 or 12 in the preparation of a kit, chip or detection system for diagnosis, auxiliary diagnosis or prognosis evaluation of Alzheimer's disease.

14. The use according to claim 13, characterized in that The sample to be tested is one or more of plasma, serum, and cerebrospinal fluid; And / or, the antigen protein marker is one or more of Aβ40, Aβ42, t-tau, p-tau181, p-tau217, and p-tau231.

Citation Information

Patent Citations

  • Methods for detecting agglutination and compositions for use in practicing the same

    CN107614699A

  • Novel coronavirus nucleic acid quantitative detection kit based on micro-droplet digital analysis

    CN112813195A

  • Method for quantifying nucleic acid and protein through two-color digital PCR (Polymerase Chain Reaction)

    CN115287339A

  • Detection method and kit

    CN117343987A

  • Biological probe for single-molecule immunodetection, detection method and application

    CN118091110A